Compare KOD & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOD | NWN |
|---|---|---|
| Founded | 2009 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2018 | 2018 |
| Metric | KOD | NWN |
|---|---|---|
| Price | $38.49 | $49.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $35.43 | ★ $54.33 |
| AVG Volume (30 Days) | ★ 868.6K | 286.0K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.71% |
| EPS Growth | N/A | ★ 36.45 |
| EPS | N/A | ★ 2.33 |
| Revenue | N/A | ★ $1,289,363,000.00 |
| Revenue This Year | N/A | $11.37 |
| Revenue Next Year | N/A | $4.46 |
| P/E Ratio | ★ N/A | $21.34 |
| Revenue Growth | N/A | ★ 11.83 |
| 52 Week Low | $4.39 | $39.29 |
| 52 Week High | $47.84 | $55.99 |
| Indicator | KOD | NWN |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 49.96 |
| Support Level | $21.82 | $48.32 |
| Resistance Level | $46.72 | $50.17 |
| Average True Range (ATR) | 2.77 | 1.08 |
| MACD | 0.61 | 0.05 |
| Stochastic Oscillator | 78.56 | 42.14 |
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.